IVERIC bio

IVERIC bio Employees

Delisted

The The number of employees of IVERIC bio (ISEE) as of Nov 3, 2026 is 44. In the previous year, The number of employees was 44.00 — a change of 0.00% (lower).

Employees

44

YoY

0.00%

Last updated:

In 2022, IVERIC bio employed 44 people, a 0.00% change from the 44.00 number of employees in the previous year.

The IVERIC bio Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2015
44.00 USD
Jan 1, 2016
44.00 USD
Jan 1, 2017
44.00 USD
Jan 1, 2018
44.00 USD
Jan 1, 2019
44.00 USD
Jan 1, 2020
44.00 USD
Jan 1, 2021
44.00 USD
Jan 1, 2022
44.00 USD
The IVERIC bio Employees history
YEAREmployeesYoY
440.00%
440.00%
440.00%
440.00%
440.00%
440.00%
440.00%
440.00%
44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Employees Details

Examining IVERIC bio's Employee Base

IVERIC bio's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding IVERIC bio's operational capacity and future potential.

Year-to-Year Comparison

Assessing IVERIC bio's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

IVERIC bio's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in IVERIC bio’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about IVERIC bio stock

The number of employees of IVERIC bio is 44 in 2022.

The number of employees of IVERIC bio changed from 44.00 to 44, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's IVERIC bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — IVERIC bio

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — IVERIC bio